Replimune Group (REPL) EBITDA

Price: $9.05
Market Cap: $696.98M
Avg Volume: 743.64K
Country: US
Industry: Biotechnology
Sector: Healthcare
Beta: 1.265
52W Range: $4.92-17
Website: Replimune Group

What is Replimune Group's EBITDA?

  • Replimune Group's annual EBITDA is $-230.20M.
  • Replimune Group's quarterly EBITDA is $-62.79M.

What is EBITDA?

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a measure of a company's overall financial performance and is used as an alternative to net income in some circumstances.

How is EBITDA calculated?

EBITDA is calculated using the following formula:

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Related Metrics

Other important metrics to assess Replimune Group's financial health include:

  • EBITDA Ratio - measures the company's EBITDA as a percentage of its revenue:
    • Annual: -
    • Quarterly: -
  • Growth EBITDA - measures the annual growth rate of the company's EBITDA:
    • Annual: -35.17%
    • Quarterly: -25.18%
  • Growth EBITDA Ratio - measures the annual growth rate of the company's EBITDA ratio:
    • Annual: 0.00%
    • Quarterly: 0.00%

These metrics provide insights into Replimune Group's financial health and its ability to meet short-term obligations. Comparing these ratios with industry benchmarks can offer a deeper understanding of the company's performance.

Annual EBITDA

$-230.20M

Quarterly EBITDA

$-62.79M

Replimune Group Historical EBITDA
Historical EBITDA Ratio (Annual)
Historical EBITDA Ratio (Quarterly)

Replimune Group Historical EBITDA Metrics

The table below shows various financial metrics for each year, with the latest data available for the last fiscal year 2024.

Year EBITDA Growth EBITDA EBITDA Ratio Growth EBITDA Ratio
2024 $-230.20M -35.17% - 0.00%
2023 $-170.30M -48.86% - 0.00%
2022 $-114.41M -49.60% - 0.00%
2021 $-76.48M -45.40% - 0.00%
2020 $-52.60M -86.05% - 0.00%
2019 $-28.27M -67.74% - 0.00%
2018 $-16.85M -108.50% - 0.00%
2017 $-8.08M 0.00% - 0.00%

Related Metrics

Explore detailed financial metrics and analysis for REPL.